- Home
- QVCG vs RNA Comparison
QVCG vs RNA Comparison
Compare QVCG & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$8.11
HOLD
Current Price
$8.15
Company Overview
Basic Information| Metric | QVCG | RNA |
|---|---|---|
| Founded | 1991 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.2M | 141.3M |
| IPO Year | 2026 | 2025 |
Fundamental Metrics
Financial Performance| Metric | QVCG | RNA |
|---|---|---|
| Price | $8.11 | $8.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 245.4K | 215.9K |
| Earning Date | N/A | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,293,000,000.00 | N/A |
| Revenue This Year | $9.11 | $84.55 |
| Revenue Next Year | $55.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.23 | $7.49 |
| 52 Week High | $18.32 | $73.06 |
Technical Indicators
Market Signals| Indicator | QVCG | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 14.67 | 41.34 |
| Support Level | N/A | $7.63 |
| Resistance Level | $18.16 | $8.50 |
| Average True Range (ATR) | 0.93 | 0.35 |
| MACD | -0.31 | 0.17 |
| Stochastic Oscillator | 1.24 | 67.33 |
Price Performance
Historical Comparison QVCG
RNA
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.